Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers material events occurring between July 7, 2026, and September 15, 2026, with the report date filed on September 15, 2026. The filing details a series of privately negotiated transactions involving the exchange of debt and preferred stock for common equity, as well as a securities purchase agreement related to a subsidiary.
Key Financial Metrics and Transactions
The filing does not provide standard financial performance metrics such as revenue, net income, operating cash flow, or liquidity ratios. Instead, it reports specific capital structure adjustments:
- Debt Reduction: The Company extinguished a 6% convertible promissory note with an outstanding balance of $175,016.36 owed to Lincoln Alternative Strategies LLC (LAS).
- Equity Issuance (Debt/Preferred Exchange):
- Issued 557,377 shares of Common Stock to LAS in exchange for the promissory note.
- Issued 272,626 shares of Common Stock to Streeterville Capital, LLC in three separate transactions (53,191, 219,435, and 31,847 shares) in exchange for 9.2 shares of Series Q Perpetual Preferred Stock.
- Equity Issuance (Securities Purchase):
- Issued 535,000 shares of Common Stock and a pre-funded warrant to purchase 2,077,255 shares of Common Stock.
- Consideration: Acquisition of all shares of Napo Therapeutics S.p.A. held by a minority shareholder.
Material Changes Versus Prior Period
The filing indicates a significant reduction in outstanding debt and preferred stock obligations, replaced by an increase in issued and outstanding common stock. Specifically, the exchange of Series Q Preferred Stock with Streeterville Capital resulted in an aggregate issuance of more than 5% of the Company's issued and outstanding shares of Common Stock as last reported in the Form 10-Q filed on August 19, 2026. The promissory note to LAS was fully surrendered and cancelled.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. The transactions were executed under exemptions from registration under Section 3(a)(9) and Section 4(a)(2) of the Securities Act of 1933. The primary risk disclosed is the dilution of existing shareholders due to the issuance of significant common stock and pre-funded warrants in exchange for debt, preferred stock, and subsidiary equity interests.
Key Facts for Investor Verification
- Verify the total number of shares issued in the Streeterville and LAS exchanges against the current share count to assess dilution impact.
- Confirm the terms of the pre-funded warrant issued to the Napo Therapeutics purchaser, including exercise price and expiration.
- Review the impact of the Napo Therapeutics acquisition on the Company's consolidated financial statements in the next quarterly report.
- Check the status of the remaining Series Q Preferred Stock, as only 9.2 shares were exchanged out of the 408 shares originally issued to Streeterville.